Faron receives IDMC recommendation to continue Phase III ARDS trial

Finland-based biopharmaceutical firm Faron Pharmaceuticals has received recommendation from the Independent Data Monitoring Committee (IDMC) to continue its Phase III clinical trial (INTEREST) of Traumakine (FP-1201-lyo) to treat moderate-to-severe a …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news